Insights into Tarsus Pharmaceuticals Q4 Earnings
Benzinga Insights 8 months ago
Earnings
Tarsus Pharmaceuticals (NASDAQ:TARS) just disclosed its Q4 earnings on Monday, February 23, 2026 at 04:05 PM.
Here's a brief overview of the earnings report.
Earnings
Tarsus Pharmaceuticals missed estimated earnings by -185.71%, reporting an EPS of $-0.2 versus an estimate of $-0.07.
Revenue was up $85.26 million from the same period last year.
Overview of Past Earnings
The company beat on EPS by $0.04 in the previous quarter, leading to a 4.62% drop share price change the next day.
Here's a look at Tarsus Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.34 | -0.35 | -0.63 | -0.82 |
| EPS Actual | -0.30 | -0.48 | -0.64 | -0.60 |
| Revenue Estimate | 115.32M | 94.84M | 71.62M | 58.80M |
| Revenue Actual | 118.70M | 102.66M | 78.33M | 66.41M |
To track all earnings releases for Tarsus Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.